The Market and Future Potential for Molecular Point of Care (POC), 2022

    Published: March 24, 2022 | Price: $5,000 – $10,000

    The Market and Future Potential for Molecular Point of Care (POC), 2022 provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings. Major IVD companies such as Abbott and Roche and Quidel compete, but there are many other and new entrants since our last reporting. Molecular point of care or mPOC systems are designed to be faster than lab-based tests while...
    The Market and Potential for Molecular Point of Care 2021

    Published: January 22, 2021 | Price: $4,000 – $8,000

    This report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings. Major IVD companies such as Abbott and Roche and Quidel compete, but there are many other and new entrants since our last reporting. Molecular point of care or mPOC systems are designed to be faster than lab-based tests while more accurate than existing point of care systems. Development of...
    The Market and Future Potential for Molecular Point of Care

    Published: March 11, 2020 | Price: $4,000 – $8,000

    THIS REPORT HAS A NEWER VERSION AVAILABLE: https://kaloramainformation.com/product/2021-molecular-point-of-care/   This report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings. Major IVD companies such as Abbott and Roche compete in this segment, influenza competitors Sekisui and Quidel also operate, as do specialty concerns such as Curetis, Biocartis, and a host of small but innovative players. Molecular point of care or...